To the Editor: Dr Melander and colleagues1 suggested that gains in risk prediction using new biomarkers for cardiovascular disease are minimal using risk reclassification, a technique that can help determine whether new markers can change clinical decisions.2 In contrast to similar analyses using data from the Women's Health Study, the Physicians' Health Study, and the Framingham Heart Study, there was no improvement in risk stratification with new markers, including C-reactive protein (CRP).
Cook NR. Biomarkers for Prediction of Cardiovascular Events. JAMA. 2009;302(19):2089-2090. doi:10.1001/jama.2009.1636